图像引导放射治疗在早期高危前列腺癌患者中进行放射剂量递增的潜在应用。
Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.
作者信息
Nguyen Nam P, Davis Rick, Bose Satya R, Dutta Suresh, Vinh-Hung Vincent, Chi Alexander, Godinez Juan, Desai Anand, Woods William, Altdorfer Gabor, D'Andrea Mark, Karlsson Ulf, Vo Richard A, Sroka Thomas
机构信息
Department of Radiation Oncology, Howard University , Washington, DC , USA.
Department of Radiation Oncology, Michael D. Wachtel Cancer Center , Oskosh, WI , USA.
出版信息
Front Oncol. 2015 Feb 2;5:18. doi: 10.3389/fonc.2015.00018. eCollection 2015.
Abstract
Patients with early stage high-risk prostate cancer (prostate specific antigen > 20, Gleason score > 7) are at high risk of recurrence following prostate cancer irradiation. Radiation dose escalation to the prostate may improve biochemical-free survival for these patients. However, high rectal and bladder dose with conventional three-dimensional conformal radiotherapy may lead to excessive gastrointestinal and genitourinary toxicity. Image-guided radiotherapy (IGRT), by virtue of combining the steep dose gradient of intensity-modulated radiotherapy and daily pretreatment imaging, may allow for radiation dose escalation and decreased treatment morbidity. Reduced treatment time is feasible with hypo-fractionated IGRT and it may improve patient quality of life.
摘要
早期高危前列腺癌（前列腺特异性抗原>20， Gleason评分>7）患者在接受前列腺癌放疗后复发风险较高。增加前列腺的放射剂量可能会改善这些患者的无生化复发生存率。然而，传统三维适形放疗时直肠和膀胱接受高剂量照射可能会导致过度的胃肠道和泌尿生殖系统毒性。图像引导放疗（IGRT）通过结合调强放疗的陡峭剂量梯度和每日治疗前成像，可能允许增加放射剂量并降低治疗并发症。短程分割IGRT可缩短治疗时间，并且可能改善患者生活质量。
相似文献
1
Potential applications of image-guided radiotherapy for radiation dose escalation in patients with early stage high-risk prostate cancer.图像引导放射治疗在早期高危前列腺癌患者中进行放射剂量递增的潜在应用。
Front Oncol. 2015 Feb 2;5:18. doi: 10.3389/fonc.2015.00018. eCollection 2015.
2
Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.图像引导的前列腺低分割放疗的晚期毒性：与常规分割的非随机比较。
Radiol Med. 2019 Jan;124(1):65-78. doi: 10.1007/s11547-018-0937-9. Epub 2018 Sep 15.
3
4
A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.一项以适应性放射治疗过程作为局部前列腺癌递送系统的剂量递增试验：慢性毒性分析。
Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):400-8. doi: 10.1016/j.ijrobp.2004.06.001.
5
Nomogram to predict rectal toxicity following prostate cancer radiotherapy.预测前列腺癌放疗后直肠毒性的列线图。
PLoS One. 2017 Jun 22;12(6):e0179845. doi: 10.1371/journal.pone.0179845. eCollection 2017.
6
Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.高剂量图像引导放疗对比非图像引导放疗在治疗局限性前列腺癌中的临床结局改善。
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9. doi: 10.1016/j.ijrobp.2011.11.047. Epub 2012 Feb 11.
7
Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.图像引导的前列腺癌低分割放疗的急性毒性：与常规分割的非随机比较。
Urol Oncol. 2011 Sep-Oct;29(5):523-32. doi: 10.1016/j.urolonc.2009.10.004. Epub 2009 Dec 16.
8
Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy.前列腺癌的放射治疗技术、剂量递增及近距离放射治疗
Clin Oncol (R Coll Radiol). 2005 Oct;17(7):560-71. doi: 10.1016/j.clon.2005.07.006.
9
Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.对于有淋巴结受累高风险的局限性疾病患者，采用大分割外照射放疗，给予前列腺≥85 Gy等效剂量进行剂量递增：可行性、耐受性和疗效。
Clin Oncol (R Coll Radiol). 2014 Jun;26(6):316-22. doi: 10.1016/j.clon.2014.02.014. Epub 2014 Mar 22.
10
Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients.现代中危前列腺癌患者队列中剂量递增的影像引导放疗与剂量递增的高剂量率近距离放疗增敏的比较。
Brachytherapy. 2014 Jan-Feb;13(1):59-67. doi: 10.1016/j.brachy.2013.05.004. Epub 2013 Jul 18.
引用本文的文献
1
Development and validation of a prognostic nomogram for neuroendocrine prostate cancer, based on the SEER database.基于监测、流行病学和最终结果（SEER）数据库的神经内分泌前列腺癌预后列线图的开发与验证
Front Surg. 2023 Mar 10;10:1110040. doi: 10.3389/fsurg.2023.1110040. eCollection 2023.
2
Targeted Chemoradiotherapy of Prostate Cancer Using Gold Nanoclusters with Protease Activatable Monomethyl Auristatin E.基于蛋白酶激活单甲基澳瑞他汀 E 的金纳米簇的前列腺癌靶向化学放疗
ACS Appl Mater Interfaces. 2022 Apr 6;14(13):14916-14927. doi: 10.1021/acsami.1c23780. Epub 2022 Mar 22.
3
Rectal dose to prostate cancer patients treated with proton therapy with or without rectal spacer.接受质子治疗且使用或未使用直肠间隔器的前列腺癌患者的直肠剂量。
J Appl Clin Med Phys. 2017 Jan;18(1):32-39. doi: 10.1002/acm2.12001. Epub 2016 Nov 21.
4
Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.多参数磁共振成像-经直肠超声融合辅助活检用于诊断前列腺癌根治术后局部复发
Urol Oncol. 2015 Oct;33(10):425.e1-425.e6. doi: 10.1016/j.urolonc.2015.05.021. Epub 2015 Aug 8.
5
The future of nanosized radiation enhancers.纳米级辐射增强剂的未来。
Br J Radiol. 2015 Oct;88(1054):20150171. doi: 10.1259/bjr.20150171. Epub 2015 Aug 7.
本文引用的文献
1
External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.前列腺癌的外照射放疗及低剂量率近距离放疗增敏，联合或不联合雄激素剥夺治疗。
Int Braz J Urol. 2014 Jul-Aug;40(4):474-83. doi: 10.1590/S1677-5538.IBJU.2014.04.05.
2
A novel approach for evaluation of prostate deformation and associated dosimetric implications in IGRT of the prostate.一种评估前列腺变形及其在前列腺图像引导放射治疗（IGRT）中相关剂量学影响的新方法。
Med Phys. 2014 Sep;41(9):091709. doi: 10.1118/1.4893196.
3
High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer.高剂量率近距离放射治疗，采用两到三次分割作为单一疗法治疗局部晚期前列腺癌。
Radiother Oncol. 2014 Jul;112(1):63-7. doi: 10.1016/j.radonc.2014.06.007. Epub 2014 Jul 10.
4
Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology.多参数3T磁共振成像在评估前列腺腺体内癌中的应用：与组织病理学的相关性
J Med Imaging Radiat Oncol. 2014 Aug;58(4):439-48. doi: 10.1111/1754-9485.12189. Epub 2014 Jun 16.
5
Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.立体定向体部放射治疗前列腺癌剂量递增 1-2 期临床试验中观察到的直肠耐受性预测因素。
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-17. doi: 10.1016/j.ijrobp.2014.03.012.
6
Cancer treatment and survivorship statistics, 2014.癌症治疗和生存统计，2014 年。
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71. doi: 10.3322/caac.21235. Epub 2014 Jun 1.
7
High-dose-rate interstitial brachytherapy in combination with androgen deprivation therapy for prostate cancer: are high-risk patients good candidates?高剂量率组织间近距离放射治疗联合雄激素剥夺治疗前列腺癌：高危患者是合适的候选者吗？
Strahlenther Onkol. 2014 Oct;190(11):1015-20. doi: 10.1007/s00066-014-0675-4. Epub 2014 May 17.
8
15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy.15 年前列腺癌近距离放射治疗后的病因特异性和全因生存率：长期激素治疗的负面影响。
J Urol. 2014 Sep;192(3):754-9. doi: 10.1016/j.juro.2014.03.094. Epub 2014 Mar 31.
9
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.接受剂量递增的低分割强度调制前列腺放射治疗的男性发生晚期毒性的风险：一项随机试验的结果。
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84. doi: 10.1016/j.ijrobp.2014.01.015.
10
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.递增剂量与常规剂量适形放疗治疗前列腺癌：MRC RT01 随机对照试验的长期结果。
Lancet Oncol. 2014 Apr;15(4):464-73. doi: 10.1016/S1470-2045(14)70040-3. Epub 2014 Feb 26.
Zotero 插件